MediciNova,Inc.
4875 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 米国カリフォルニア州ラ・ホイヤ、スウィート３００、エグゼクティブ・スクエア４２７５
- Website:
- https://medicinova.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
MediciNova, Inc. is a Japanese biopharmaceutical company dedicated to developing innovative therapeutics targeting neurology, respiratory, and liver diseases that currently lack effective treatments. The company's lead product, MN-221, is aimed at addressing acute exacerbations in asthma and chronic obstructive pulmonary disease (COPD). Additionally, MediciNova is advancing MN-001, a therapeutic candidate focused on fibrotic diseases, including liver fibrosis related to non-alcoholic steatohepatitis (NASH) and pulmonary fibrosis associated with idiopathic pulmonary fibrosis (IPF). With a commitment to addressing unmet medical needs, MediciNova strives to improve patient outcomes through its cutting-edge research and development efforts.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-25 03:32 |
Inside Information Statement
臨時報告書
|
Japanese | 16.6 KB | |
| 2025-06-10 06:52 |
Internal Control over Financial Reporting
内部統制報告書
|
Japanese | 51.3 KB | |
| 2025-06-10 06:51 |
Regulatory News Service
確認書
|
Japanese | 12.9 KB | |
| 2025-06-10 06:50 |
Annual Report
有価証券報告書
|
Japanese | 3.0 MB | |
| 2024-09-11 04:32 |
Regulatory News Service
確認書
|
Japanese | 13.0 KB | |
| 2024-09-11 04:28 |
Interim Report
半期報告書
|
Japanese | 436.9 KB | |
| 2024-06-17 09:06 |
Inside Information Statement
臨時報告書
|
Japanese | 15.4 KB | |
| 2024-06-13 05:03 |
Regulatory News Service
確認書
|
Japanese | 13.1 KB | |
| 2024-06-13 05:02 |
Quarterly Report
四半期報告書
|
Japanese | 424.9 KB | |
| 2024-06-10 09:48 |
Internal Control over Financial Reporting
内部統制報告書
|
Japanese | 51.4 KB | |
| 2024-06-10 09:46 |
Annual Report
有価証券報告書
|
Japanese | 3.3 MB | |
| 2024-06-10 09:46 |
Regulatory News Service
確認書
|
Japanese | 12.9 KB | |
| 2023-12-12 06:01 |
Regulatory News Service
確認書
|
Japanese | 13.1 KB | |
| 2023-12-12 06:00 |
Quarterly Report
四半期報告書
|
Japanese | 418.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |